Comparative Pharmacology
Head-to-head clinical analysis: PEMAZYRE versus SORAFENIB TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMAZYRE versus SORAFENIB TOSYLATE.
PEMAZYRE vs SORAFENIB TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
Sorafenib is a multikinase inhibitor that inhibits Raf serine/threonine kinases (C-Raf, B-Raf, and mutant B-Raf), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor (PDGFR-β), and other kinases, thereby inhibiting tumor cell proliferation and angiogenesis.
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
400 mg orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
Terminal half-life of sorafenib is approximately 25-48 hours (mean ~37 hours); clinical steady-state achieved within 7 days.
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Fecal (77%) as unchanged drug and metabolites; renal (19%) as glucuronide conjugates; <1% excreted unchanged in urine.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor